依考匹泮 T31602

Product Introduction
Bioactivity


英文名: Ecopipam

描述: Ecopipam (UNII-0X748O646K) 是一种有效的、选择性、具有口服活性的多巴胺 D1/D5 受体拮抗剂，Ki 值分别为 1.2 nM 和 2.0 nM。Ecopipam 对 D2、D4、5-HT 和 α2a 受体 (Ki=0.98，5.52，0.08 和 0.73 μM) 显示出超过 40 倍的选择性。Ecopipam 可用于精神分裂症、可卡因成瘾和肥胖症的研究。

体外活性: Ecopipam (2 μM) 完全消除了在分离的皮质海马形成中[2]，多巴胺 (10 μM) 的促癫痫效应。

体内活性: Ecopipam (0.003-0.3 mg/kg; a single s.c.) abolishes Nicotine-induced enhancement of a sensory reinforcer in adult rats[3]. Ecopipam (10, mg/kg, oral administration) antagonizes Apomorphine-induced stereotypy in rats[4]. Ecopipam (5 and 10 μM, perfusion, 1 μL/min) reversibly and dose-dependently decreases acetylcholine release in the rat striatum[5].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

关键字: Ecopipam

相关产品: Triflupromazine hydrochloride | Clebopride malate | D-tetrahydropalmatine | Xaliproden hydrochloride | Flunarizine dihydrochloride | Syrosingopine | Oxolinic acid | Tipepidine hydrochloride | PZ-1190 | BMY 7378 dihydrochloride

相关库: Anti-Neurodegenerative Disease Compound Library | Neurotransmitter Receptor Compound Library | ReFRAME Related Library | Anti-Cancer Drug Library | Clinical Compound Library | Membrane Protein-targeted Compound Library | Neuronal Signaling Compound Library | Anti-Cancer Clinical Compound Library | GPCR Compound Library

依考匹泮 T31602信息由TargetMol中国为您提供，如您想了解更多关于依考匹泮 T31602报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途